These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 20059760)

  • 1. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred?
    Schrezenmeier H; Seifried E
    Vox Sang; 2010 Jul; 99(1):1-15. PubMed ID: 20059760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ethics of wasting the donor's gift of buffy coat.
    Vamvakas EC
    Vox Sang; 2011 Feb; 100(2):256-7; author reply 258-9. PubMed ID: 20825600
    [No Abstract]   [Full Text] [Related]  

  • 3. Disparate risks and effects of pooled whole blood-derived vs. apheresis platelet production require an integral view on the blood supply.
    Zimmermann R; Blasczyk R; Zingsem J; Eckstein R; Heuft HG
    Vox Sang; 2010 Oct; 99(3):295-6; author reply 297-8. PubMed ID: 20561324
    [No Abstract]   [Full Text] [Related]  

  • 4. [Platelet concentrates from whole-blood donations (buffy-coat) or apheresis: which one to use?].
    Lozano ML; Rivera J; Vicente V
    Med Clin (Barc); 2012 May; 138(12):528-33. PubMed ID: 21807386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A critical comparison of platelet preparation methods.
    Vassallo RR; Murphy S
    Curr Opin Hematol; 2006 Sep; 13(5):323-30. PubMed ID: 16888436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation, storage and quality control of platelet concentrates.
    Tynngård N
    Transfus Apher Sci; 2009 Oct; 41(2):97-104. PubMed ID: 19699153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pooled platelet concentrates: an alternative to single donor apheresis platelets?
    Pietersz RN
    Transfus Apher Sci; 2009 Oct; 41(2):115-9. PubMed ID: 19716340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet concentrates, from whole blood or collected by apheresis?
    van der Meer PF
    Transfus Apher Sci; 2013 Apr; 48(2):129-31. PubMed ID: 23535511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality and safety of platelet apheresis concentrates produced with a new leukocyte reduction system.
    Riggert J; Humpe A; Simson G; Köhler M
    Vox Sang; 1998; 74(3):182-8. PubMed ID: 9595646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of random versus apheresis platelet concentrates.
    Andreu G; Vasse J; Sandid I; Tardivel R; Semana G
    Transfus Clin Biol; 2007 Dec; 14(6):514-21. PubMed ID: 18417401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet activation of platelet concentrates derived from buffy coat and apheresis methods.
    Ali SF
    Transfus Apher Sci; 2011 Feb; 44(1):11-3. PubMed ID: 21277261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro function of buffy coat-derived platelet concentrates stored for 9 days in CompoSol, PASII or 100% plasma in three different storage bags.
    Cardigan R; Sutherland J; Garwood M; Bashir S; Turner C; Smith K; Hancock V; Wiltshire M; Pergande C; Williamson LM
    Vox Sang; 2008 Feb; 94(2):103-12. PubMed ID: 18034786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet storage lesion in interim platelet unit concentrates: A comparison with buffy-coat and apheresis concentrates.
    Singh S; Shams Hakimi C; Jeppsson A; Hesse C
    Transfus Apher Sci; 2017 Dec; 56(6):870-874. PubMed ID: 29126740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Single-donor (apheresis) platelets and pooled whole-blood-derived platelets--significance and assessment of both blood products].
    Hitzler WE
    Clin Lab; 2014; 60(4):S1-39. PubMed ID: 24779310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical effect of buffy-coat vs. apheresis platelet concentrates in patients with severe thrombocytopenia after intensive chemotherapy.
    Akkök CA; Brinch L; Lauritzsen GF; Solheim BG; Kjeldsen-Kragh J
    Vox Sang; 2007 Jul; 93(1):42-8. PubMed ID: 17547564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracellular accumulation of bioactive substances during preparation and storage of various platelet concentrates.
    Edvardsen L; Taaning E; Dreier B; Christensen LD; Mynster T; Nielsen HJ
    Am J Hematol; 2001 Jul; 67(3):157-62. PubMed ID: 11391711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and storage of white blood cell-reduced split apheresis platelet concentrates for pediatric use.
    van der Meer PF; Vrielink H; Pietersz RN
    Transfusion; 2005 Feb; 45(2):223-7. PubMed ID: 15660831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Impact-R for monitoring the platelet storage lesion.
    Albanyan AM; Murphy MF; Harrison P
    Platelets; 2009 Feb; 20(1):1-6. PubMed ID: 19172514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of cytokine accumulation in platelets obtained with the COBE spectra apheresis system.
    Palmer DS; Aye MT; Dumont L; Dumont D; McCombie N; Giulivi A; Rutherford B; Trudel E; Hashemi-Tavoularis S
    Vox Sang; 1998; 75(2):115-23. PubMed ID: 9784664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relative safety of pooled whole-blood-derived platelets prepared by the buffy-coat method versus single-donor (apheresis) platelets.
    Vamvakas EC
    Clin Lab; 2010; 56(7-8):263-79. PubMed ID: 20857891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.